Journal article
Effectiveness and safety of bedaquilinecontaining regimens in the treatment of MDR- and XDR-TB: A multicentre study
SE Borisov, K Dheda, M Enwerem, RR Leyet, L D'Ambrosio, R Centis, G Sotgiu, S Tiberi, JW Alffenaar, A Maryandyshev, E Belilovski, S Ganatra, A Skrahina, O Akkerman, A Aleksa, R Amale, J Artsukevich, J Bruchfeld, JA Caminero, IC Martinez Show all
European Respiratory Journal | EUROPEAN RESPIRATORY SOC JOURNALS LTD | Published : 2017
Abstract
Large studies on bedaquiline used to treat multidrug-resistant (MDR-) and extensively drug-resistant tuberculosis (XDR-TB) are lacking. This study aimed to evaluate the safety and effectiveness of bedaquiline-containing regimens in a large, retrospective, observational study conducted in 25 centres and 15 countries in five continents. 428 culture-confirmed MDR-TB cases were analysed (61.5% male; 22.1% HIV-positive, 45.6% XDRTB). MDR-TB cases were admitted to hospital for a median (interquartile range (IQR)) 179 (92-280) days and exposed to bedaquiline for 168 (86-180) days. Treatment regimens included, among others, linezolid, moxifloxacin, clofazimine and carbapenems (82.0%, 58.4%, 52.6% an..
View full abstractGrants
Awarded by National Institute for Health Research (NIHR)